Anti-Rheumatics Market by Drug Class (Disease Modifying Anti-Rheumatic Drugs (DMARD's), Nonsteroidal Anti-Inflammatory Drugs (NSAID's), Corticosteroids, Uric Acid Drugs, and Others), Type (Prescription-Based Drugs and Over-the-Counter Drugs): Global Opportunity Analysis and Industry Forecast, 2019–2026
- ALL3757780
- 202 Pages
- January 2020
- Healthcare
Rheumatoid arthritis (RA) is a chronic auto-immune disorder that majorly affects joints along with articular tissues and extra-articular organs. Furthermore, this medical condition is often progressive and results in pain, stiffness, and swelling of joints. Moreover, there is no permanent cure for RA, the goals of the treatment are to reduce pain, decrease inflammation, prevent bone deformity, and improve a person’s overall function. This is achieved through pain medication, steroids, and NSAIDs that are frequently used to help with the symptoms. In addition, disease-modifying anti-rheumatic drugs (DMARDs) are used to slow down the progression of this disease. These drugs are the primary treatment for RA and have been found to improve symptoms, decrease joint damage, and improve overall functional abilities. However, early diagnosis and early treatment is the key for better management of the disease. Recent advancements with biosimilars, which may be used to treat RA and increase in approvals of the same by regulatory authorities have opened new avenues for the anti-rheumatics market.
The major factors that fuel the growth of the global rheumatoid arthritis drugs market include rise in incidence of rheumatoid arthritis and surge in geriatric population across the globe. In addition, increase in incidence of obesity worldwide is another major factor that drives the growth of anti-rheumatic market. However, side effects associated with the medication and higher cost of biologics & biosimilars restrain the growth of rheumatoid arthritis drug market. On the contrary, developments in the field of biosimilars and novel biologics are anticipated to offer profitable opportunities for the growth of the RA drugs market.
The anti-rheumatics market size is studied on the basis of drug class, type, and region to provide a detailed assessment of the market. On the basis of drug class, it is divided into disease modifying anti-rheumatic drugs (DMARD's), nonsteroidal anti-inflammatory drugs (NSAID's), corticosteroids, uric acid drugs, and others. By type, it is divided into prescription-based drugs and over-the-counter drugs. By region, the anti-rheumatics market size is analyzed across North America (the U.S., Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global anti-rheumatics market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
• By Drug Class
o Disease Modifying Anti-rheumatic Drugs (DMARD's)
o Nonsteroidal Anti-inflammatory Drugs (NSAID's)
o Corticosteroids
o Uric Acid Drugs
o Others
• By Type
o Prescription-Based Drugs
o Over-the-Counter Drugs
• By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
List of key players profiled in the report:
• Pfizer, Inc.
• Johnson & Johnsons
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Celegene Corporations
• MedImmune, LLC
• Takeda Pharmaceutical Company Ltd.
• Biogen Inc.
• Celltrion Inc.
• Amgen Inc
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Sebela Pharmaceuticals
• Abbott LaboratoriesSafe In Breastfeeding
1.1. Report description
1.2. Key market segments
1.2.1. List of key players profiled in the report
1.3. Research methodology
1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Key forces shaping anti-rheumatics industry/market
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in geriatric population across the globe
3.4.1.2. Surge in healthcare expenditure worldwide
3.4.1.3. Rise in prevalence of rheumatoid arthritis across the globe
3.4.2. Restraint
3.4.2.1. Patent expirations of blockbuster drugs
3.4.3. Opportunity
3.4.3.1. High growth potential in developing economies
3.4.4. Impact Analyses
CHAPTER 4: ANTI-RHEUMATICS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Disease Modifying Anti-Rheumatic Drugs
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country
4.3. Nonsteroidal Anti-inflammatory Drugs
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country
4.4. Corticosteroids
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis by country
4.5. Uric Acid Drugs
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis by country
4.6. Others
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis by country
CHAPTER 5: ANTI-RHEUMATICS MARKET, BY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Prescription-Based Drugs
5.2.1. Market size and forecast, by region
5.2.2. Market analysis by country
5.3. Over-the-Counter Drugs
5.3.1. Market size and forecast, by region
5.3.2. Market analysis by country
CHAPTER 6: ANTI-RHEUMATICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. Market analysis, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by drug class
6.2.2.1.2. U.S. market size and forecast, by type
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by drug class
6.2.2.2.2. Canada market size and forecast, by type
6.2.2.3. Mexico
6.2.2.3.1. Mexico market size and forecast, by drug class
6.2.2.3.2. Mexico market size and forecast, by type
6.2.3. North America market size and forecast, by drug class
6.2.4. North America market size and forecast, by type
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Market analysis, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by drug class
6.3.2.1.2. Germany market size and forecast, by type
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by drug class
6.3.2.2.2. France market size and forecast, by type
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by drug class
6.3.2.3.2. UK market size and forecast, by type
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by drug class
6.3.2.4.2. Italy market size and forecast, by type
6.3.2.5. Rest of Europe
6.3.2.5.1. Rest of Europe market size and forecast, by drug class
6.3.2.5.2. Rest of Europe market size and forecast, by type
6.3.3. Europe market size and forecast, by drug class
6.3.4. Europe market size and forecast, by type
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Market analysis, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by drug class
6.4.2.1.2. Japan market size and forecast, by type
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by drug class
6.4.2.2.2. China market size and forecast, by type
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by drug class
6.4.2.3.2. India market size and forecast, by type
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by drug class
6.4.2.4.2. Rest of Asia-Pacific market size and forecast, by type
6.4.3. Asia-Pacific market size and forecast, by drug class
6.4.4. Asia-Pacific market size and forecast, by type
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. Market analysis, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil market size and forecast, by drug class
6.5.2.1.2. Brazil market size and forecast, by type
6.5.2.2. South Africa
6.5.2.2.1. South Africa market size and forecast, by drug class
6.5.2.2.2. South Africa market size and forecast, by type
6.5.2.3. Saudi Arabia
6.5.2.3.1. Saudi Arabia market size and forecast, by drug class
6.5.2.3.2. Saudi Arabia market size and forecast, by type
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA market size and forecast, by drug class
6.5.2.4.2. Rest of LAMEA market size and forecast, by type
6.5.3. LAMEA market size and forecast, by drug class
6.5.4. LAMEA market size and forecast, by type
CHAPTER 7: COMPANY PROFILES
7.1. AbbVie Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Amgen Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. BRISTOL-MYERS SQUIBB COMPANY
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. Eli Lilly And Company
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. F. HOFFMANN-LA ROCHE LTD.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. Johnson & Johnson
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. Merck & Co., Inc
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Novartis AG
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Pfizer Inc.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. UCB S.A.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
TABLE 01. GLOBAL ANTI-RHEUMATICS MARKET, BY DRUG CLASS, 2018-2026 ($MILLION )
TABLE 02. DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ANTI-RHEUMATICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ANTI-RHEUMATICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. CORTICOSTEROIDS ANTI-RHEUMATICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. URIC ACID DRUGS ANTI-RHEUMATICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. OTHERS ANTI-RHEUMATICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. GLOBAL ANTI-RHEUMATICS MARKET, BY TYPE, 2018-2026 ($MILLION )
TABLE 08. PRESCRIPTION-BASED ANTI-RHEUMATICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. OVER-THE-COUNTER ANTI-RHEUMATICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10. ANTI-RHEUMATICS MARKET, BY REGION, 2018-2026 ($MILLION )
TABLE 11. NORTH AMERICA ANTI-RHEUMATICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 12. U.S. ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 13. U.S. ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 14. CANADA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 15. CANADA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 16. MEXICO ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 17. MEXICO ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 18. NORTH AMERICA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 19. NORTH AMERICA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026($MILLION)
TABLE 20. EUROPE ANTI-RHEUMATICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 21. GERMANY ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 22. GERMANY ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 23. FRANCE ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 24. FRANCE ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 25. UK ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 26. UK ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 27. ITALY ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 28. ITALY ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 29. REST OF EUROPE ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 30. REST OF EUROPE ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 31. EUROPE ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 32. EUROPE ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026($MILLION)
TABLE 33. ASIA-PACIFIC ANTI-RHEUMATICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 34. JAPAN ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 35. JAPAN ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 36. CHINA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 37. CHINA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 38. INDIA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 39. INDIA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 40. REST OF ASIA-PACIFIC ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 41. REST OF ASIA-PACIFIC ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 42. ASIA-PACIFIC ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 43. ASIA-PACIFIC ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026($MILLION)
TABLE 44. LAMEA ANTI-RHEUMATICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 45. BRAZIL ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 46. BRAZIL ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 47. SOUTH AFRICA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 48. SOUTH AFRICA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 49. SAUDI ARABIA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 50. SAUDI ARABIA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 51. REST OF LAMEA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 52. REST OF LAMEA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 53. LAMEA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 54. LAMEA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026($MILLION)
TABLE 55. ABBVIE: COMPANY SNAPSHOT
TABLE 56. ABBVIE: OPERATING SEGMENTS
TABLE 57. ABBVIE: PRODUCT PORTFOLIO
TABLE 58. AMGEN: COMPANY SNAPSHOT
TABLE 59. AMGEN: OPERATING SEGMENTS
TABLE 60. AMGEN: PRODUCT PORTFOLIO
TABLE 61. BMS: COMPANY SNAPSHOT
TABLE 62. BMS: OPERATING SEGMENTS
TABLE 63. BMS: PRODUCT PORTFOLIO
TABLE 64. LILLY : COMPANY SNAPSHOT
TABLE 65. LILLY: OPERATING SEGMENTS
TABLE 66. LILLY: PRODUCT PORTFOLIO
TABLE 67. ROCHE: COMPANY SNAPSHOT
TABLE 68. ROCHE: OPERATING SEGMENTS
TABLE 69. ROCHE: PRODUCT PORTFOLIO
TABLE 70. J&J: COMPANY SNAPSHOT
TABLE 71. J&J: OPERATING SEGMENTS
TABLE 72. JOHNSON & JOHNSON: PRODUCT PORTFOLIO:
TABLE 73. MERCK: COMPANY SNAPSHOT
TABLE 74. MERCK: OPERATING SEGMENTS
TABLE 75. MERCK: PRODUCT PORTFOLIO
TABLE 76. NOVARTIS: COMPANY SNAPSHOT
TABLE 77. NOVARTIS: OPERATING SEGMENTS
TABLE 78. NOVARTIS: PRODUCT PORTFOLIO
TABLE 79. PFIZER: COMPANY SNAPSHOT
TABLE 80. PFIZER: OPERATING SEGMENTS
TABLE 81. PFIZER: PRODUCT PORTFOLIO
TABLE 82. UCB: COMPANY SNAPSHOT
TABLE 83. UCB: PRODUCT SEGMENTS
TABLE 84. UCB: PRODUCT PORTFOLIO
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
